Testing and News
VeriSci received Phase I and Phase II SBIR
grants from the National Institutes of Health to develop and commercialize devices for use in clinical settings:
early detection and monitoring
VeriSci has received funds from the National Eye Institute (NEI) of the NIH
for development of a commercial device for quick assessment of early-stage glaucoma. The clinical test result was reported
in the following article: Zemon, V., Tsai, J.C., Forbes, M., Al-Aswad,
L., Chen, C.M., Dhrami-Gavazi, E., Gordon, J., Greenstein, V., Hu, G., Strugstad, E.C., Jindra, L.F. Novel
electrophysiological instrument for rapid and objective assessment of magnocellular deficits associated with glaucoma.
Doc. Ophthal., 2008, 117, 233-243.
A multi-site study on early-stage glaucomatous damage has been completed in collaboration with scientists and
clinicians at Columbia University Medical Center, Yale University School of Medicine, University of Tennessee Health Science
Center, University of Virginia School of Medicine, and the University of Alabama at Birmingham School of Optometry. Click
"Glaucoma" to see the test results.
The test for assessment of visual neural development in infants and young children employs a rapid sweep of stimuli
(bars of different widths - different spatial frequencies) to efficiently and objectively measure neural mechanisms of spatial
vision. Currently, the Neucodia system is used by leading clinicians and scientists for intensive clinical studies on
visual disorders in infants and young children's. Click
"Amblyopia" to see more information.
A clinical study on early-stage diabetic retinopathy has been conducted in collaboration
with scientists and clinicians at Yale University
School of Medicine. The result has been submitted for publication.
schizophreniaVeriSci has received funds from the
National Institute of Mental Health (NIMH) of the NIH for the development of a commercial device to serve as an electrophysiological
biomarker for schizophrenia. Currently, clinical testing at the Nathan S. Kline Institute for Psychiatric Research, New
York University (NYU) has been completed. The results will be submitted soon for publication. The device includes a unique
battery of tests, which includes ones recognized by NIMH as recommended for perceptual/cognitive assessment of individuals